This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

A Safety and Efficacy Trial Evaluating the Use of Fondaparinux in Percutaneous Coronary Intervention (PCI)(63133)(WITHDRAWN)

This study has been withdrawn prior to enrollment.
(Drug sold to Sanofi-Aventis who sold it to GSK; OBS no longer owns study and does not have data.)
Information provided by:
Schering-Plough Identifier:
First received: May 7, 2003
Last updated: November 2, 2009
Last verified: November 2009
The purpose of this research study is to obtain experience in the use of fondaparinux (Arixtra) as compared to heparin when administered to patients who undergo percutaneous coronary intervention (PCI). PCI is a mechanical procedure used to widen the narrowing in a coronary artery in patients with symptomatic coronary artery disease. Fondaparinux and heparin are drugs that inhibit blood clotting.

Condition Intervention Phase
Myocardial Infarction Coronary Disease Drug: fondaparinux sodium Drug: heparin Procedure: percutaneous coronary intervention (PCI) Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by Schering-Plough:

Estimated Enrollment: 300
Study Start Date: April 2003

Ages Eligible for Study:   21 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion criteria

  • Scheduled for PCI, including PCI for non-ST elevation acute coronary syndromes (ACS), primary PCI for ST elevation myocardial infarction (MI) or elective PCI (with planned overnight stay in hospital). (Patients undergoing diagnostic heart catherization who are suitable candidates for "ad hoc" PCI are also eligible).

Exclusion criteria:

  • Age < 21 years
  • Activated Clotting Time (ACT) > 200 seconds immediately prior to PCI
  • Use of low molecular weight heparin (LMWH) in the previous 6 hours before PCI
  • Currently receiving an oral anticoagulant (OAC) agent with an INR > 1.8
  • Thrombolytic therapy for ST elevation MI in the previous 24 hours before PCI
  • Active internal bleeding or history of hemorrhagic diathesis
  • Thrombocytopenia (platelet count < 100 x 10-9/L)
  • Pregnant women or women of childbearing potential who are not using an effective method of contraception
  • Known allergy to unfractionated heparin, fondaparinux, aspirin or clopidogrel
  • Absolute contra-indication to anticoagulation
  • Participation in other clinical research studies involving the evaluation of other investigational drugs or devices within 30 days of enrollment or prior participation in this study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00060554

  Show 26 Study Locations
Sponsors and Collaborators
  More Information

Responsible Party: Head, Clinical Trials Registry & Results Disclosure Group, Schering-Plough Identifier: NCT00060554     History of Changes
Other Study ID Numbers: 63133 (ASPIRE-Pilot)
Study First Received: May 7, 2003
Last Updated: November 2, 2009

Keywords provided by Schering-Plough:
Elective PCI
Heart catherization
Acute coronary syndromes

Additional relevant MeSH terms:
Myocardial Infarction
Coronary Disease
Coronary Artery Disease
Pathologic Processes
Myocardial Ischemia
Heart Diseases
Cardiovascular Diseases
Vascular Diseases
Arterial Occlusive Diseases
Fibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action processed this record on August 22, 2017